Leukocyte-Rich vs. Leukocyte-Poor Platelet-Rich Plasma for Knee Osteoarthritis
Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized TrialAm J Sports Med. 2022 Mar;50(3): 609-617.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
192 patients with unilateral, symptomatic knee osteoarthritis were randomized to receive 3 weekly intra-articular injections of leukocyte-rich platelet-rich plasma (n=96) or leukocyte-poor platelet-rich plasma (n=96). The primary outcome of interest was the International Knee Documentation Committee (IKDC) score at 12 months. Secondary outcomes of interest included the Knee Injury and Osteoarthrit...
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.Continue